Microscopic Colitis

A chronic, relapsing, and recurring inflammatory condition of the colon causing non-bloody diarrhea, characterized by grossly normal-appearing colonic mucosa with abnormal histologic findings — distinguishing it from Infectious Colitis and IBD, both of which typically show macroscopic mucosal changes. Content below is from a textbook reference chapter (ASCRS Ch53 - Radiation, Microscopic, and Ischemic Colitis), not primary literature.

Definition and subtypes

Two subtypes, distinguished only histologically, with identical presentation and management:

• Collagenous colitis (CC) — subepithelial collagen band ≥10 μm thick. The collagen band decreases in thickness with treatment, but symptom severity correlates with lamina propria inflammation rather than collagen band size.
• Lymphocytic colitis (LC) — increased proportion of surface intraepithelial lymphocytes; collagen band, if present, is <10 μm.

Debate persists over whether CC and LC represent two distinct diseases or differing presentations of one entity.

Epidemiology

Incidence has risen substantially in tracked cohorts — a Minnesota study found combined CC+LC incidence rising from ~8.6/100,000 in the late 1980s (3.1/100,000 CC, 5.5/100,000 LC) to 19.6/100,000 by 2001; European data show a comparable rise across the 1990s (1.1→5.2/100,000); some recent estimates run as high as 219/100,000. Whether this reflects a true incidence increase or increased awareness/diagnostic rate is unclear. Mean age at diagnosis is 61, with increasing incidence with age (though presentation in middle age and, rarely, childhood, does occur). There is a female predominance (OR 2–8), suggesting a hormonal or genetic contribution.

Risk factors

Autoimmune association is strong: 40% of MC patients have another autoimmune disorder (type 1 diabetes mellitus, autoimmune thyroiditis, polyarteritis — polyarteritis carries an OR of 20.8 for CC and 8 for LC). 40% of celiac disease patients also demonstrate MC-consistent histologic changes. No direct genetic link has been identified, but familial clustering is observed, and HLA/TNF-alpha gene polymorphisms (which predispose to autoimmune disorders generally) are more frequent in MC patients. Microbiome alterations have been observed but are not yet clinically actionable. Prior infection with Yersinia enterocolitica and prior C. difficile infection (see Infectious Colitis) have both been associated with subsequent MC — supporting a model where an outside antigen triggers disease in a genetically predisposed host, though causation is unproven.

Smoking is associated with increased MC incidence and an earlier age at diagnosis (one 2013 study of 248 patients: OR 2.4 for CC, 3.8 for LC); smoking cessation is recommended in management, though no study has shown it induces remission.

Medications: NSAIDs (OR 3.8 CC / 4.7 LC), PPIs (OR 6.4 CC / 2.7 LC), SSRIs, and statins have all shown association with MC, though a direct cause-and-effect relationship has not been established — a large Pennsylvania database study failed to replicate a medication-MC correlation. One proposed explanation for the discrepancy: diarrhea as a medication side effect may itself prompt the colonoscopic evaluation that leads to incidental MC diagnosis in otherwise normal individuals. Even without proven causation, discontinuing suspect medications is a reasonable initial management step.

Manifestations and course

Watery, non-bloody diarrhea is the predominant symptom; active disease is defined as ≥3 bowel movements/day plus ≥1 episode of nighttime diarrhea. Other associated symptoms: abdominal pain, fecal incontinence, weight loss, fatigue. Despite significant quality-of-life impact, MC resolves in most patients — 75% achieve remission (no symptoms off medication for 1 year) — though symptoms commonly recur, making this an intermittent, relapsing, chronic disease for many patients. Spontaneous remission (without medication) is associated with more durable remission than drug-induced remission. MC is generally a benign disease: it does not increase colorectal cancer risk and has actually been associated with a decreased incidence of colorectal adenomas. Serious complications (spontaneous or colonoscopy-associated colonic perforation) are rare.

Diagnosis

Criteria (Spanish Microscopic Colitis Group): chronic or intermittent non-bloody diarrhea, plus macroscopically normal/near-normal colonic mucosa on colonoscopy, plus characteristic histopathological appearance on biopsy. Differential diagnosis includes IBD, IBS, bile acid malabsorption, celiac disease, small intestinal bacterial overgrowth, and lactose intolerance — overlap between these conditions and MC can occur. No laboratory study is diagnostic; fecal calprotectin is nonspecifically elevated in MC (one study: mean 175 μg/g vs. 28 μg/g in controls) and cannot establish the diagnosis or monitor treatment on its own. Imaging is normal and useful mainly to exclude other causes of colitis.

Colonoscopy is mandatory. Full colonoscopy — not flexible sigmoidoscopy — is required, with two biopsies taken from each colonic segment throughout the colon; sampling only the rectum or sigmoid reduces diagnostic sensitivity, since characteristic changes may not be present throughout the entire colon. Mucosa is grossly normal or near-normal (uncommonly, altered vascular patterns — pale mucosa, erythema, edema, linear ulcers — may be seen); frank inflammatory bowel disease findings should be absent. Among patients undergoing colonoscopy with appropriate biopsies for symptoms consistent with MC, 10–15% are ultimately found to have the disease. Histology shows lamina propria inflammation (increased lymphocytes and plasma cells) with generally preserved crypt architecture (cryptitis may be present); routine H&E staining is usually sufficient, though CD3 staining can better visualize intraepithelial lymphocytes when the diagnosis is in question.

Management

Anti-diarrheal medications (loperamide, diphenoxylate) are used by most patients and improve symptoms without inducing remission or reducing histologic inflammation. Probiotics show no benefit over placebo. Bismuth salicylate has small-study support: one double-blind RCT of 14 patients found 100% clinical success vs. 0% with placebo, and a meta-analysis found an 81% overall response rate (dosing: three 262mg tablets TID for 8 weeks, mean response at 2 weeks). Antibiotic data (metronidazole, erythromycin, penicillin) comes only from small studies and cannot yet be recommended.

Budesonide is the evidence-based mainstay of treatment. A double-blind RCT randomizing 57 patients to budesonide, mesalamine, or placebo found budesonide superior (68% success vs. 21% placebo, 26% mesalamine); a large trial-and-maintenance study (110 patients) found 84% induction success with budesonide, and among responders randomized to budesonide 4.5mg/day maintenance vs. placebo, 61% remained in remission at 1 year vs. 16% on placebo — demonstrating budesonide's usefulness for both induction and maintenance/recurrent disease. Recurrence after stopping budesonide is common but the drug can be restarted successfully. Prednisolone can also induce remission but only a moderate response is typically seen, at greater steroid-side-effect cost, and it has not been shown superior to budesonide — so it is not favored for primary therapy. Immunomodulators (6-MP, azathioprine, anti-TNF-alpha agents) have shown good results only in very small studies/case reports; given MC's generally benign course, their use is limited to rare severe, budesonide-refractory disease with life-disabling symptoms.

Surgical management is not part of a standard treatment algorithm. Occasional patients with treatment failure and life-disabling symptoms warrant surgery — diversion (with or without colonic resection) is the mainstay surgical approach, and both provide symptomatic improvement plus a demonstrable decrease in biopsy-proven inflammation (in CC, collagen band thickness decreases after diversion). The theoretical benefit of diversion alone is the potential to restore continuity later, but symptoms recur if the ostomy is reversed. Two case reports describe total proctocolectomy with IPAA for this indication with acceptable results, but there is no data supporting this as a standard management strategy.

Summary treatment ladder: smoking cessation (if applicable) and discontinuation of associated medications → anti-diarrheal medications for mild disease → budesonide for persistent symptoms (induction, then maintenance if recurrence-prone) → immunomodulators for rare severe/refractory disease → diversion ± resection as a last resort for medically refractory, life-disabling disease.

Open items / gaps

• All content above is textbook-level/secondary. Three load-bearing named sources are flagged in Research Priorities.md for independent ingestion: the Miehlke and Münch budesonide RCTs, and the Spanish Microscopic Colitis Group (Fernandez-Banares) consensus statement that is the source of the diagnostic criteria used above.
• No data yet in the wiki on how MC is distinguished from its overlap conditions (IBS, bile acid malabsorption, celiac disease, SIBO) in practice beyond listing them as differentials.